Antidepressants May Blur the Warning Sign Hidden in Dream-Enacting Sleep

Every night, in the deepest stretch of dreaming sleep, the healthy brain performs a remarkable trick: it switches off the body. During rapid eye movement, or REM, sleep, a network of brainstem circuits actively paralyzes nearly every muscle below the head, pinning the dreamer in place while the mind races through vivid hallucinations. When that paralysis fails, the result is a phenomenon called REM sleep without atonia, the electrophysiological signature of a condition that can spill dreams into bedrooms in the form of punching, kicking, and shouting. For decades, clinicians have treated this loss of muscle tone suppression as a red flag, because in many people it heralds serious neurodegenerative disease. But a new letter to the editor, published in the Journal of Clinical Sleep Medicine by Abdul Basit Munir, Haider Imran, and Nashmia Faraz of Foundation University Medical College in Islamabad, argues that the picture is far more complicated for the millions of people who take antidepressants, and that the field needs to widen how it interprets this finding in that population.

The stakes of this debate are unusually high. REM sleep behavior disorder, the clinical condition that arises when dream enactment accompanies loss of REM atonia, is now recognized as one of the most powerful early warning signs in all of medicine. Longitudinal cohort studies, including the landmark observational work by Alex Iranzo and colleagues published in The Lancet Neurology, followed patients diagnosed with idiopathic REM sleep behavior disorder, meaning cases with no obvious cause, and found that a large proportion went on to develop Parkinson’s disease or dementia with Lewy bodies, with post-mortem examination in some cases confirming synuclein pathology, the same protein abnormality that underlies those disorders. A subsequent multicenter study led by Ronald Postuma and an international team, published in the journal Brain, confirmed across dozens of centers that idiopathic REM sleep behavior disorder carries a substantial risk of incident dementia and parkinsonism over time. In practical terms, a polysomnography report showing REM sleep without atonia can set in motion years of anxious monitoring, counseling about future neurodegeneration, and even screening for enrollment in preventive drug trials targeting alpha-synuclein before symptoms emerge.

Into this high-stakes diagnostic arena steps a confounder that sleep clinicians have wrestled with for years: antidepressant medication. Since the early 2000s, accumulating evidence has linked the most widely prescribed antidepressants, particularly selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, with both REM sleep behavior disorder symptoms and the underlying electrophysiological abnormality of REM sleep without atonia. The mechanisms are thought to involve serotonergic and noradrenergic modulation of the brainstem circuitry that governs REM atonia, effectively interfering with the switch that paralyzes the dreaming body. Postuma and colleagues raised the central question in a 2013 paper in the journal Sleep, asking whether antidepressant-associated REM sleep behavior disorder is an isolated side effect of the drugs or a neurodegenerative signal, a medication unmasking a process that was already underway. That question has never been fully resolved, and it sits at the heart of the new letter.

The letter responds directly to a recent quantitative study by Joumana Ahdab, Claudio Rodriguez, Margaret Grigg-Damberger, and colleagues, published in the same journal, which examined how different antidepressant medications have differential effects on REM sleep without atonia when it is quantified by chin and upper extremity electromyography. That work matters because the measurement itself is not straightforward. Polysomnography scoring of REM sleep without atonia depends on which muscles are sampled, how much electrical activity is counted as excessive, and which scoring rules are applied. The chin EMG channel is the traditional standard, but abnormal movements in REM sleep behavior disorder often manifest most dramatically in the limbs, and studies have shown that adding upper extremity EMG channels can substantially increase detection. Ahdab and colleagues’ finding that specific antidepressants differ in how much they elevate muscle tone during REM sleep, and that the effect varies depending on whether chin or arm muscles are measured, adds a crucial layer of nuance to a diagnostic system that often treats REM sleep without atonia as a binary yes-or-no finding.

Munir and his coauthors use this new evidence to argue for an expanded interpretation of the phenomenon. The core of their argument is that REM sleep without atonia in an antidepressant user cannot be read through the same lens as the same finding in a medication-free patient. If different drugs push the EMG signal in different directions, and if the choice of muscle group changes the result, then a single polysomnographic reading in a person taking, say, an SSRI may reflect a pharmacological effect on brainstem motor control rather than an early degenerative process. Interpreting such a finding as automatically equivalent to idiopathic REM sleep behavior disorder risks mislabeling patients, generating unwarranted fear of impending Parkinson’s disease or dementia, and potentially steering people away from effective psychiatric treatment out of alarm about their sleep study results.

At the same time, the letter’s authors are careful not to swing the pendulum too far in the other direction, because dismissing REM sleep without atonia in antidepressant users as a harmless side effect carries its own dangers. The 2013 Postuma analysis in Sleep found evidence pointing in both directions: antidepressant-associated REM sleep behavior disorder shares features with the idiopathic form, and some researchers have proposed that the medications may act as an unmasking agent, revealing subclinical neurodegeneration that would otherwise have remained silent for years. Under this model, a person whose brainstem inhibitory circuits are already being eroded by early synuclein disease has less reserve to resist the atonia-suppressing effects of serotonergic drugs, so the medication does not create the vulnerability but exposes it. If that model is correct, then REM sleep without atonia in an antidepressant user may still be a meaningful prognostic sign, and simply attributing it to the prescription would mean missing an opportunity for early surveillance.

The practical implications for clinical practice are considerable. Sleep physicians scoring a polysomnogram currently face a genuine interpretive dilemma when the patient’s medication list includes an antidepressant. Guidelines for REM sleep behavior disorder diagnosis do not fully account for drug effects on quantitative EMG measures, and there is no established algorithm for distinguishing pharmacological REM sleep without atonia from a neurodegenerative prodrome. The letter suggests that interpretation should be broadened to incorporate the medication context explicitly: which antidepressant the patient is taking, at what dose, for how long, whether the abnormal muscle tone is confined to the chin or extends to the limbs, and whether there is actual dream enactment behavior rather than isolated EMG abnormality. A finding of elevated chin tone alone in a patient who recently started a serotonergic antidepressant and has never acted out a dream is a very different clinical entity from violent nocturnal behaviors in a long-term user with limb movements and autonomic or olfactory changes suggestive of early parkinsonism.

The letter also underscores a broader lesson about how biomarkers travel from the research laboratory into everyday medicine. Quantitative REM atonia measures were developed and validated largely in cohorts carefully selected to answer specific research questions, often excluding people taking psychotropic medications precisely because those drugs confound the signal. When those same measures are applied in routine clinical polysomnography, where antidepressant use is common and often unremarked, the interpretive framework does not automatically come along with the measurement. The Islamabad authors’ contribution is to insist that the field close this gap, developing medication-aware reference ranges and interpretive standards so that a polysomnographic number means the same thing regardless of the patient’s pharmacy. Until that happens, they argue, clinicians should treat REM sleep without atonia in antidepressant users as a finding requiring nuanced judgment rather than a fixed diagnostic verdict.

What makes this debate resonate beyond the sleep laboratory is its window into the brain’s chemistry of dreaming. The fact that a daily pill for depression can loosen the grip of the paralysis that normally binds us to the mattress is a vivid reminder that the boundary between the dreaming mind and the waking body is actively maintained by specific neurotransmitter systems, and that those systems can be nudged by the medicines we take for entirely different purposes. Whether that nudging is benign, or whether it occasionally illuminates a disease process smoldering years before its first tremor, remains one of the most consequential open questions in sleep medicine. The letter by Munir, Imran, and Faraz does not settle it, but it makes a persuasive case that the answer will not come from treating all REM sleep without atonia as one thing. As antidepressant use continues to rise worldwide and as preventive trials for synucleinopathies move closer to reality, getting this interpretation right will determine who is told to worry, who is reassured, and who is offered a genuine head start against diseases that medicine has so far only been able to diagnose too late.

Subject of Research: REM sleep without atonia in antidepressant users and its implications for REM sleep behavior disorder diagnosis

Article Title: Expanding the interpretation of REM sleep without atonia in antidepressant users

Article References: Munir, A. B., Imran, H., & Faraz, N. (2026). Expanding the interpretation of REM sleep without atonia in antidepressant users. Journal of Clinical Sleep Medicine, 22(1), Article 147. https://doi.org/10.1007/s44470-026-00167-8

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00167-8

Keywords: REM sleep, REM sleep behavior disorder, antidepressants, polysomnography, sleep medicine, neurodegeneration, Parkinson's disease, dementia, SSRIs, psychopharmacology, EMG, sleep disorders